Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment

Acta Biochimica et Biophysica Sinica

Volumn 43, Issue 6, 2011, Pages 487-495

  Ouyang, Dongyun ^a   Zhang, Yanting ^a   Xu, Lihui ^a   Li, Jingjing ^a   Zha, Qingbing ^a   He, Xianhui ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

apoptosis; autophagy; cucurbitacin B; melanoma; synergistic effect; valproic acid

Indexed keywords

CHLOROQUINE; CUCURBITACIN B; HISTONE DEACETYLASE INHIBITOR; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; TRITERPENE; VALPROIC ACID;

ANIMAL; APOPTOSIS; ARTICLE; AUTOPHAGY; BIOSYNTHESIS; DRUG EFFECT; DRUG POTENTIATION; MELANOMA; MOUSE; TUMOR CELL LINE; UPREGULATION;

ANIMALS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CHLOROQUINE; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MELANOMA; MICE; PROTO-ONCOGENE PROTEINS C-BCL-2; TRITERPENES; UP-REGULATION; VALPROIC ACID;

EID: 79958260109     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmr032     Document Type: Article

References (48)

1. Trinh VA. Current management of metastatic melanoma. Am J Health Syst Pharm 2008, 65: S3-S8.
2. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R and Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003, 63: 1270-1279. (Pubitemid 36348705)
3. Wakimoto N, Yin D, O'Kelly J, Haritunians T, Karlan B, Said J and Xing H, et al. Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci 2008, 99: 1793-1797.
4. Yin D, Wakimoto N, Xing H, Lu D, Huynh T, Wang X and Black KL, et al. Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 2008, 123: 1364-1375.
5. Haritunians T, Gueller S, Zhang L, Badr R, Yin D, Xing H and Fung MC, et al. Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk Res 2008, 32: 1366-1373.
6. Zhang M, Sun C, Shan X, Yang X, Li-Ling J and Deng Y. Inhibition of pancreatic cancer cell growth by cucurbitacin B through modulation of signal transducer and activator of transcription 3 signaling. Pancreas 2010, 39: 923-929.
7. Liu T, Zhang M, Zhang H, Sun C and Deng Y. Inhibitory effects of cucurbitacin B on laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol 2008, 265: 1225-1232.
8. Yasuda S, Yogosawa S, Izutani Y, Nakamura Y, Watanabe H and Sakai T. Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells. Mol Nutr Food Res 2010, 54: 559-565.
9. Chan KT, Meng FY, Li Q, Ho CY, Lam TS, To Y and Lee WH, et al. Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett 2010, 294: 118-124.
10. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R and Ciliberto G, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10: 105-115. (Pubitemid 29077388)
11. Garcia R and Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci 1998, 5: 79-85. (Pubitemid 28253097)
12. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB and Sung B, et al. Targeting signal-transducer-and-activator-oftranscription- 3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006, 1091: 151-169. (Pubitemid 47092233)
13. Richon VM, Sandhoff TW, Rifkind RA and Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000, 97: 10014-10019.
14. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW and Moon EJ, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001, 7: 437-443. (Pubitemid 32298546)
15. Di GE, Bruzzese F, Pepe S, Leone A, Delrio P, Subbarayan PR and Avallone A, et al. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther 2009, 8: 782-791.
16. Wittenburg LA, Bisson L, Rose BJ, Korch C and Thamm DH. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol 2011, 67: 83-92.
17. Hubaux R, Vandermeers F, Crisanti MC, Kapoor V, Burny A, Mascaux C and Albelda SM, et al. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Eur J Cancer 2010, 46: 1724-1734.
18. Kristensen LS, Nielsen HM and Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009, 625: 131-142.
19. Bacon CL, Gallagher HC, Haughey JC and Regan CM. Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase. J Neurochem 2002, 83: 12-19.
20. Batty N, Malouf GG and Issa JP. Histone deacetylase inhibitors as antineoplastic agents. Cancer Lett 2009, 280: 192-200.
21. Chan KT, Li K, Liu SL, Chu KH, Toh M and Xie WD. Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett 2010, 289: 46-52.
22. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA and Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276: 36734-36741.
23. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA and Brill B, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003, 22: 3411-3420. (Pubitemid 36834871)
24. Gottlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 2004, 83 Suppl 1: S91-S92.
25. Wek RC, Jiang HY and Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 2006, 34: 7-11. (Pubitemid 43235522)
26. Kouroku Y, Fujita E, Tanida I, Ueno T, Isoai A, Kumagai H and Ogawa S, et al. ER stress (PERK/eIF2alpha phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. Cell Death Differ 2007, 14: 230-239. (Pubitemid 46092226)
27. Karna P, Zughaier S, Pannu V, Simmons R, Narayan S and Aneja R. Induction of reactive oxygen species-mediated autophagy by a novel microtubule-modulating agent. J Biol Chem 2010, 285: 18737-18748.
28. Eum KH and Lee M. Crosstalk between autophagy and apoptosis in the regulation of paclitaxel-induced cell death in v-Ha-ras-transformed fibroblasts. Mol Cell Biochem 2011, 348: 61-68.
29. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M and Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000, 10: 886-895. (Pubitemid 30647617)
30. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273: 5858-5868. (Pubitemid 28124064)
31. Chen S, Rehman SK, Zhang W, Wen A, Yao L and Zhang J. Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta 2010, 1806: 220-229.
32. Liu T, Peng H, Zhang M, Deng Y and Wu Z. Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. Eur J Pharmacol 2010, 641: 15-22.
33. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010, 19: 1049-1066.
34. Bokelmann I and Mahlknecht U. Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med 2008, 14: 20-27. (Pubitemid 351356882)
35. Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Gottlicher M and Gregor M, et al. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 2005, 42: 210-217. (Pubitemid 40143467)
36. Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY and Ng DC. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim Biophys Acta 2010, 1804: 463-475.
37. Lorin S, Borges A, Ribeiro Dos SL, Souquere S, Pierron G, Ryan KM and Codogno P, et al. c-Jun NH2-terminal kinase activation is essential for DRAM-dependent induction of autophagy and apoptosis in 2-methoxyestradiol- treated Ewing sarcoma cells. Cancer Res 2009, 69: 6924-6931.
38. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y and Siddik ZH, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003, 278: 19245-19256. (Pubitemid 36799316)
39. Chen Y, Wu Q, Song SY and Su WJ. Activation of JNK by TPA promotes apoptosis via PKC pathway in gastric cancer cells. World J Gastroenterol 2002, 8: 1014-1018. (Pubitemid 35446412)
40. Sanchez-Perez I, Murguia JR and Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998, 16: 533-540. (Pubitemid 28062081)
41. Lim CP and Cao X. Regulation of Stat3 activation by MEK kinase 1. J Biol Chem 2001, 276: 21004-21011.
42. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C and Dey S, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 2009, 1171: 59-76.
43. Barre B, Avril S and Coqueret O. Opposite regulation of myc and p21waf1 transcription by STAT3 proteins. J Biol Chem 2003, 278: 2990-2996. (Pubitemid 36801206)
44. Tannin-Spitz T, Grossman S, Dovrat S, Gottlieb HE and Bergman M. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol 2007, 73: 56-67. (Pubitemid 44853933)
45. Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE and Gopalakrishnan V. Valproic acid induces p21 and topoisomerase-II (alpha/ beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007, 85: 159-170. (Pubitemid 47629397)
46. Rocchi P, Tonelli R, Camerin C, Purgato S, Fronza R, Bianucci F and Guerra F, et al. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep 2005, 13: 1139-1144.
47. Jung GA, Yoon JY, Moon BS, Yang DH, Kim HY, Lee SH and Bryja V, et al. Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathway. BMC Cell Biol 2008, 9: 66.
48. Ahmed-Choudhury J, Williams KT, Young LS, Adams DH and Afford SC. CD40 mediated human cholangiocyte apoptosis requires JAK2 dependent activation of STAT3 in addition to activation of JNK1/2 and ERK1/2. Cell Signal 2006, 18: 456-468. (Pubitemid 41790366)